Humana Inc. $HUM Stock Purchased by Lido Advisors LLC

Lido Advisors LLC lifted its stake in shares of Humana Inc. (NYSE:HUM – Free Report) by 54.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,461 shares of the insurance provider’s stock after buying an additional 2,628 shares during the period. Lido Advisors LLC’s holdings in Humana were worth $2,847,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Pinnacle Wealth Planning Services Inc. raised its position in Humana by 21.8% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 151 shares of the insurance provider’s stock valued at $58,000 after purchasing an additional 27 shares during the last quarter. Wilkerson Advisory Group LLC grew its position in shares of Humana by 24.6% in the 2nd quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider’s stock valued at $66,000 after buying an additional 33 shares during the last quarter. Cidel Asset Management Inc. raised its position in shares of Humana by 1.1% during the second quarter. Cidel Asset Management Inc. now owns 3,883 shares of the insurance provider’s stock worth $1,542,000 after acquiring an additional 41 shares during the last quarter. Greenleaf Trust lifted its stake in shares of Humana by 1.7% in the third quarter. Greenleaf Trust now owns 2,524 shares of the insurance provider’s stock worth $963,000 after acquiring an additional 41 shares during the period. Finally, 71 West Capital Partners lifted its stake in shares of Humana by 4.3% in the third quarter. 71 West Capital Partners now owns 1,030 shares of the insurance provider’s stock worth $393,000 after acquiring an additional 42 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Deutsche Bank initiated coverage on Humana in a report on Thursday, July 30th. They issued a “hold” rating on the stock. Leerink Partners upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 price target on the stock in a research report on Thursday, July 30th. Wells Fargo & Company boosted their price target on shares of Humana from $502.00 to $602.00 and gave the stock an “overweight” rating in a research report on Thursday. Robert W. Baird raised shares of Humana from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $390.00 to $596.00 in a research note on Friday, October 9th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $420.00 price objective on shares of Humana in a research report on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Humana presently has a consensus rating of “Moderate Buy” and a consensus target price of $476.52.

Read Our Latest Stock Report on HUM

Humana Stock Performance

NYSE HUM opened at $450.38 on Monday. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $456.50. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.65 and a quick ratio of 1.65. The company has a fifty day moving average price of $408.53 and a 200-day moving average price of $316.91. The firm has a market cap of $54.09 billion, a price-to-earnings ratio of 43.81, a PEG ratio of 2.14 and a beta of 0.65.

Humana (NYSE:HUM – Get Free Report) last announced its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. The firm had revenue of $41.16 billion for the quarter, compared to the consensus estimate of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The company’s revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.24 EPS. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, equities research analysts predict that Humana Inc. will post 9.66 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 24th will be given a $0.8850 dividend. The ex-dividend date of this dividend is Thursday, December 24th. This represents a $3.54 annualized dividend and a yield of 0.8%. Humana’s payout ratio is currently 34.44%.

Insider Transactions at Humana

In other Humana news, insider Joseph Ventura sold 5,495 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the completion of the transaction, the insider owned 21,910 shares in the company, valued at $9,505,653.50. This represents a 20.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is owned by company insiders.

Humana Profile

(Free Report)

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Featured Stories

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.